旭輝控股(00884.HK)向執行董事林峯授出425.56萬股獎勵股份
格隆匯9月24日丨旭輝控股(00884.HK)發佈公告,董事會議決於2020年9月24日根據股份獎勵計劃向執行董事林峯先生授出425.56萬股股份。該等獎勵股份將於2020年9月25日或之後歸屬予林峯先生(或彼所指定而彼為受益人的家族信託)。
於本公告日期,受託人持有合共5379萬股股份,其中5102.6萬股股份為受託人根據股份獎勵計劃及信託契據的條款於公開市場上購入,以及276.36萬股股份為根據公司的以股代息計劃發行予信託人的代息股份。獎勵股份相當於公司於本公告日期已發行股份總數約0.05%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.